Immunogenicity of a novel DNA vaccine cassette expressing multiple human immunodeficiency virus (HIV-1) accessory genes

AIDS

Volumn 14, Issue 1, 2000, Pages 1-9

  Ayyavoo, Velpandi ^a   Kudchodkar, Sagar ^a   Ramanathan, Mathura P ^a   Le, Phong ^a   Muthumani, Karuppiah ^a   Megalai, Natesan Mani ^a   Dentchev, Tzvete ^a   Santiago Barrios, Limaris ^a   Mrinalini, Conjeevaram ^a   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cell mediated response; Fusion protein; Gene construct; HIV 1; Immune response; Immunogen; T helper cell; Vaccine

Indexed keywords

ANTIGEN; CYTOKINE; DNA VACCINE; HYBRID PROTEIN; NEF PROTEIN; VIF PROTEIN; VPU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CODING; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE CONSTRUCT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; TH1 CELL; VACCINATION; VIRUS GENE; VIRUS INFECTION;

3T3 CELLS; ANIMALS; BLOTTING, WESTERN; CELL DIVISION; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; FLUORESCENT ANTIBODY TECHNIQUE; GENE PRODUCTS, NEF; GENE PRODUCTS, VIF; GENE PRODUCTS, VPU; HELA CELLS; HIV-1; HUMANS; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; TRANSFECTION; VACCINATION; VACCINES, DNA;

EID: 0033969803     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200001070-00001     Document Type: Article

References (34)

1. 1. Myers G, Korber B, Barzofsky JA, Smith RF, Pavalakis CN. Human retroviruses and AIDS. Theoretical Biology and Biophysics Group T-10. Los Alamos NM: Los Alamos National Laboratory; 1992.
2. 2. Trono D. HIV accessory proteins: leading roles for the supporting cast. Cell 1995, 82:189-192.
3. 3. Emerman M, Malim MH. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 1998, 280:1880-1884.
4. 4. Culler, B.R. HIV-1 Auxiliary proteins: making connections in a dying cell. Cell 1998, 93:685-692.
5. 5. Sova P, Van Ranst M, Gupta P, et al. The conservation of intact human immunodeficiency virus type 1 (HIV-1) vif gene in primary virus isolates from symptomatic and asymptomatic individuals and in vivo. J Virol 1995, 69:2557-2564.
6. 6. Zhang L, Huang L, Yuan H, Tuttleton S, Ho DD. Genetic characterization of vif, vpr, and vpu sequences from long-term survivors of human immunodeficiency virus type 1 infection. Virology 1997, 228:340-349.
7. 7. Balliet JW, Kolson DL, Eiger C, Kim FM, McCann KA, Srinivasan A, Collman RA. Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu and nef: mutational analysis of a primary HIV-1 isolate. Virology 1994, 200:623-631.
8. 8. Kirchhoff F, Easterbrook PJ, Douglas N, et al. Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. J. Virol 73:5497-5508.
9. 9. Korber BTM, Moore JP, et al. HIV Molecular Immunology Database. Theoretical Biology and Biophysics 1999. Los Alamos, NM: Los Alamos National Laboratory, 1999.
10. 10. Gotch F. Cross-clade T cell recognition of HIV-1. Curr Opin Immunol 1998, 10:388-392.
11. 11. Ayyavoo V, Nagashunmugam T, Boyer J, et al. Development of genetic vaccine for pathogenic genes: construction of attenuated vif DNA immunization cassettes. AIDS 1997, 11:1433-1444.
12. 12. Michael NL, Chang G, d'Arcy LA, et al. Defective accessory genes in a human immunodeficiency virus type1-infected long-term survivor lacking recoverable virus. J Virol 1995, 69:4228-4236.
13. 13. Ayyavoo V, Mahboubi A, Mahalingam S, et al. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kB. Nat Med 1997, 3:1117-1123.
14. 14. Poon B, Grovit-Ferbas KS, Strwart SA, Chen ISY. Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents. Science 1998, 281:266-269.
15. 15. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989, 77:51-59.
16. 16. Mahalingam S, Ayyavoo V, Patel M, Kieber-Emmons T, Weiner DB. Nuclear import, virion incorporation and cell cycle arrest/ differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J Virol 1997, 71:6339-6347.
17. 17. Wang B, Ugen EK, Srikantan V, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1, Proc Natl Acad Sci USA 1993, 90:4156-4160.
18. 18. Kim JJ, Ayyavoo V, Bagarazzi M, et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997 158:816-826.
19. 19. Deng H, Unutmaz D, KewalRamani VN, Littman DR. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 1997, 388:296-300.
20. 20. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994, 76:241-251.
21. 21. Arai K, Miyajima A, Miyatake S, Arai N, Tokota T. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 1990, 59:783-836.
22. 22. Hinkula J, Svanholm C, Schwartz S, et al. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol 1997, 71:5528-5539.
23. 23. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650-4655.
24. 24. Borrow P, Lewicki H, Hahn H, Shaw GM, Oldstone MBA. Virus-specific CD8 ' cytotoxic T lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994, 68:6103-6110.
25. 25. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993, 177:249-256.
26. 26. Harrer T, Harrer E, Kalams SA, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 1996, 156:2616-2623.
27. 27. Oggs GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998, 279:2103-2106.
28. 28. Klein MR, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995, 181:1365-1372.
29. 29. Rinaldo C, Huang XL, Fan ZF, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term non-progressors. J Virol 1995, 69:5838-5342.
30. 30. Cheynier R, Langladedemoyen P, Marescot MR, et al. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers. Eur J Immunol 1992, 22: 2211-2217.
31. 31. McMichael AJ, Walker BD. Cytotoxic T lymphocyte epitopes: implications for HIV vaccines. AIDS 1994, 8 (Suppl. 1):S155.
32. 32. Salk J, Bretscher PA, Salk PL, Clerici M, Shearer CM. A strategy for prophylactic vaccination against HIV. Science 1993, 260:1270-1272.
33. 33. Durali D, Morvan J, Letourneur F, et al. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients. J Virol 1998, 72:3547-3453.
34. 34. Ferrari G, Humphrey W, McElrath et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivates in uninfected volunteers. Proc. Natl. Acad. Sci. USA 1997, 94:1396-1401.